The coactivation of STAT3 and Yes1 associated transcriptional regulator (YAP1) has also been associated with the promotion of tumor cell survival after EGFR TKI treatment, and the co-inhibition of EGFR, STAT3, and Src-YAP1 signaling demonstrates a more effective synergistic effect than the single use of an EGFR TKI [139]. The gene discussed is EGFR; the disease is neoplasm.